Figure 4.

Mouse AML cells are sensitive to ZEB2 inhibition. (A) Log₂ fold depletions of Zeb2 shRNA in the in vivo screen. (B) qPCR of Zeb2 mRNA level at day 6 after infection. (C) Immunoblotting of ZEB2 at day 6 after infection. (D) Competitive proliferation assay of leukemia cells infected with Zeb2 shRNA and control shRNA. Error bars indicate SD (n = 3). (E) Frequency of mutated Zeb2 genomic alleles at 4.5 days after sgRNA infection. (F) Competitive proliferation assay of leukemia cells stably expressing Cas9 after infection with sgRNAs. Error bars indicate SD (n = 3).